Welcome to The Visible Embryo
  o
 
The Visible Embryo Birth Spiral Navigation
   
Google  
Fetal Timeline--- -Maternal Timeline-----News-----Prescription Drugs in Pregnancy---- Pregnancy Calculator----Female Reproductive System

   
WHO International Clinical Trials Registry Platform

The World Health Organization (WHO) has a Web site to help researchers, doctors and patients obtain information on clinical trials.

Now you can search all such registers to identify clinical trial research around the world!






Home

History

Bibliography

Pregnancy Timeline

Prescription Drug Effects on Pregnancy

Pregnancy Calculator

Female Reproductive System

News

Disclaimer: The Visible Embryo web site is provided for your general information only. The information contained on this site should not be treated as a substitute for medical, legal or other professional advice. Neither is The Visible Embryo responsible or liable for the contents of any websites of third parties which are listed on this site.


Content protected under a Creative Commons License.
No dirivative works may be made or used for commercial purposes.

 

Pregnancy Timeline by SemestersDevelopmental TimelineFertilizationFirst TrimesterSecond TrimesterThird TrimesterFirst Thin Layer of Skin AppearsEnd of Embryonic PeriodEnd of Embryonic PeriodFemale Reproductive SystemBeginning Cerebral HemispheresA Four Chambered HeartFirst Detectable Brain WavesThe Appearance of SomitesBasic Brain Structure in PlaceHeartbeat can be detectedHeartbeat can be detectedFinger and toe prints appearFinger and toe prints appearFetal sexual organs visibleBrown fat surrounds lymphatic systemBone marrow starts making blood cellsBone marrow starts making blood cellsInner Ear Bones HardenSensory brain waves begin to activateSensory brain waves begin to activateFetal liver is producing blood cellsBrain convolutions beginBrain convolutions beginImmune system beginningWhite fat begins to be madeHead may position into pelvisWhite fat begins to be madePeriod of rapid brain growthFull TermHead may position into pelvisImmune system beginningLungs begin to produce surfactant
CLICK ON weeks 0 - 40 and follow along every 2 weeks of fetal development




 
Developmental biology - Progeria

Free treatment for children with Progeria

Eiger BioPharmaceuticals is dispensing its drug lonafarnib as free treatment for children with Progeria...


The Progeria Research Foundation Announced on May 16, 2018 a Collaboration with Eiger BioPharmaceuticals under FDA Guidance: Lonafarnib Approval for Progeria and are now looking for children with the ultra-rare and fatal, rapid-aging disease. Progeria children die of heart disease at an average age of 14 years old.

The collaboration and supply agreement with Eiger BioPharmaceuticals is for pursuit and development of U.S. Food and Drug Administration approval of lonafarnib as treatment for Progeria in children. This is the first therapy ever submitted to the FDA for treatment of Progeria.
Occurring in approximately 400 children worldwide, Progeria is caused by a genetic mutation that results in an overabundance of the protein named progerin.

Following PRF’s co-discovery of this mutation, the Foundation funded additional studies showing that, although progerin accumulation within blood vessels is typically seen in normal aging, it is highly accelerated in Progeria which causes progressive cellular damage and atherosclerosis in childhood.

Without treatment, children with Progeria die of heart disease at an average age of 14.5 years.

Lonafarnib inhibits farnesyltransferase, an enzyme that facilitates the production ofprogerin. As a farnesyltransferase inhibitor (FTI), lonafarnib helps prevent cellular damage caused by the mutant protein. However, Lonafarnib is not currently approved for use outside of clinical trials.

Since 2007, PRF has funded four clinical trials to study lonafarnib’s effect on Progeria ± treating children from more than 30 countries. PRF Medical Director Leslie Gordon MD PhD, along with her research teams at Boston Children’s Hospital and Brown University, recently published results of a study of lonafarnib in Progeria in The Journal of the American Medical Association (JAMA). The study reported that treatment with lonafarnib alone compared against no treatment was associated with a significantly lower mortality rate (3.7% vs. 33.3%) after a median of 2.2 years of follow up (see JAMA citations below).

“This progress is due in large part to the courage and strength of children with Progeria and their families who participated in the lonafarnib clinical trials,” explains Dr. Gordon. “More than a decade of intensive investigation has enabled PRF to strike this partnership with Eiger and move towards potential FDA review and approval. Reaching this tremendous milestone gives us even more optimism that we will discover additional treatments that complement the lonafarnib therapy and keep us moving forward towards more effective treatments and the cure.” As the parents of Sam Berns, who died in 2014 at the age of 17, with Progeria, Dr. Gordon and her husband, Scott Berns, MD MPH co-founded PRF in 1999 with Gordon’s sister Audrey Gordon, Esq.

Merck, known as MSD outside of the United States and Canada, previously provided lonafarnib free of charge for use in PRF-sponsored clinical trials. Following a transfer of manufacturing technology from Merck in 2015, Eiger began to provide lonafarnib at no cost for use in ongoing clinical trials funded by PRF. Eiger has since expanded its licensing agreement with Merck to include rights to develop lonafarnib for the treatment of Progeria and will be responsible for regulatory execution, commercialization and distribution activities across the licensed and approved indications in the future.

PRF has granted Eiger a non-exclusive, world-wide license to all PRF intellectual property, know-how and clinical data generatedby PRF to prepare and file a new drug application (NDA) for Progeria. Eiger also intends to establish an expanded access program that would enable access to lonafarnib for children with Progeria.“Continued patient access to lonafarnib was the fundamental motivation for this agreement with PRF,” explains David Cory, President and CEO of Eiger. “Eiger will provide lonafarnib for ongoing clinical trials and expanded access in Progeria and work together with PRF to seek regulatory guidance on a pathway toward regulatory approval of lonafarnib for use in children with Progeria.”

• In 2003 the PRF Genetics Consortium discovered the Progeria gene, a collaboration led by Dr. Francis Collins, then Director of the National Human Genome Research Institute, and currently Director of the National Institutes of Health (NIH).

• Today, PRF continues to be the only organization in the world solely dedicated to finding treatments and the cure for Progeria and its aging-related conditions, including heart disease.

• The organization takes Progeria children out of the medical background where they had been for more than 100 years and puts them and Progeria at the forefront of scientific efforts.

• For more information and to donate to PRF, please visit www.progeriaresearch.org.

Abstract
Importance: Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare fatal premature aging disease. There is no approved treatment.

Objective: To evaluate the association of monotherapy using the protein farnesyltransferase inhibitor lonafarnib with mortality rate in children with HGPS.

Design, Setting, and Participants: Cohort study comparing contemporaneous (birth date >=1991) untreated patients with HGPS matched with treated patients by age, sex, and continent of residency using conditional Cox proportional hazards regression. Treatment cohorts included patients from 2 single-group, single-site clinical trials (ProLon1 [n = 27; completed] and ProLon2 [n = 36; ongoing]). Untreated patients originated from a separate natural history study (n = 103). The cutoff date for patient follow-up was January 1, 2018.

Exposure: Treated patients received oral lonafarnib (150 mg/m2) twice daily. Untreated patients received no clinical trial medications.

Main Outcomes and Measures: The primary outcome was mortality. The primary analysis compared treated patients from the first lonafarnib trial with matched untreated patients. A secondary analysis compared the combined cohorts from both lonafarnib trials with matched untreated patients.

Results: Among untreated and treated patients (n = 258) from 6 continents, 123 (47.7%) were female; 141 (54.7%) had a known genotype, of which 125 (88.7%) were classic (c.1824C>T in LMNA). When identified (n = 73), the primary cause of death was heart failure (79.4%). The median treatment duration was 2.2 years. Median age at start of follow-up was 8.4 (interquartile range [IQR], 4.8-9.5) years in the first trial cohort and 6.5 (IQR, 3.7-9.0) years in the combined cohort. There was 1 death (3.7%) among 27 patients in the first trial group and there were 9 deaths (33.3%) among 27 patients in the matched untreated group. Treatment was associated with a lower mortality rate (hazard ratio, 0.12; 95% CI, 0.01-0.93; P = .04). In the combined cohort, there were 4 deaths (6.3%) among 63 patients in the treated group and 17 deaths (27.0%) among 63 patients in the matched untreated group (hazard ratio, 0.23; 95% CI, 0.06-0.90; P = .04).

Conclusions and Relevance: Among patients with HGPS, lonafarnib monotherapy, compared with no treatment, was associated with a lower mortality rate after 2.2 years of follow-up. Study interpretation is limited by its observational design.

JAMA reference: Gordon et. al., Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome, JAMA, April 24, 2018 Volume 319, Number 16 and accompanying editorial..

Authors: Leslie B. Gordon MD PhD; Heather Shappell PhD; Joe Massaro PhD; Ralph B. D’Agostino Sr PhD; Joan Brazier MS; Susan E. Campbell MA; Monica E. Kleinman MD; Mark W. Kieran MD PhD.


Acknowledgements
About Eiger BioPharmaceuticals, Inc.: Eiger BioPharmaceuticals (NASDAQ: EIGR) is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare diseases. Eiger is committed to translational innovation and the development of well-characterized drugs acting on newly identified or novel targets. Eiger’s mission is to systematically reduce the time and cost of the drug development process to more rapidly deliver important medicines to patients with rare diseases. Eiger’s lead program evaluating lonafarnib in Hepatitis Delta Virus (HDV) infection is moving into Phase 3 with a single, pivotal trial planned to initiate by the end of the year. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Return to top of page

Jun 4, 2018   Fetal Timeline   Maternal Timeline   News   News Archive




The Progeria Research Foundation (PRF) was founded in 1999 by Leslie B. Gordon MD PhD, Sam's mother and Scott Berns, MD MPH, Sam's father in 1999 along with Gordon’s sister Audrey Gordon, Esq. in response to the complete lack of attention to, and progress being made in Progeria research. Their original mission: to discover the cause, treatments and cure for Progeria. Be sure to view Sam's TED talk: Sam Berns


Phospholid by Wikipedia